Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review

References

• Uyl-de Groot CA, de GS, Steenhoek A. The economics of improved cancer survival rates: better outcomes, higher costs. Expert Rev Pharmacoecon Outcomes Res 2010;10(3):283-92
   PubMed Web of Science ®Google Scholar
• Drummond M, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. 1st edition. Oxford University Press; New York: 1987
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for HealthEconomic Evaluation. Oxford University Press, Oxford, UK; 2014
   Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10(8):779-87
   PubMed Web of Science ®Google Scholar
• Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ 2007;16(2):195-209
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices--overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making 2012;32(5):667-77
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313(7052):275-83
   PubMed Web of Science ®Google Scholar
• Evers S, Goossens M, de VH, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care 2005;21(2):240-5
   PubMed Web of Science ®Google Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24(4):355-71
   PubMed Web of Science ®Google Scholar
• Frederix GW, Severens JL, Hovels AM, et al. The cloudy crystal ball of cost-effectiveness studies. Value Health 2013;16(6):1100-2
   Google Scholar
• Frederix GW, van Hasselt JG, Schellens JH, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics 2014;32(1):47-61
   Google Scholar
• Bolin K, Forsgren L. The cost effectiveness of newer epilepsy treatments a review of the literature on partial-onset seizures. Pharmacoeconomics 2012;30(10):903-23
   PubMed Web of Science ®Google Scholar
• Bongers ML, Coupe VM, Jansma EP, et al. Cost Effectiveness of treatment with new agents in advanced non-small-cell lung cancer a systematic review. Pharmacoeconomics 2012;30(1):17-34
   PubMed Web of Science ®Google Scholar
• Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012;30(1):63-80
   PubMed Web of Science ®Google Scholar
• Frederix GW, Severens JL, Hovels AM, et al. Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. Value Health 2012;15(1):94-105
   PubMed Web of Science ®Google Scholar
• John-Baptiste A, Yeung MW, Leung V, et al. Cost Effectiveness of hepatitis c-related interventions targeting substance users and other high-risk groups a systematic review. Pharmacoeconomics 2012;30(11):1015-34
   Google Scholar
• Colchero MA, Caro-Vega YN, Sanchez-Gonzalez G, Bautista-Arredondo S. A literature review of reporting standards of HIV progression models. AIDS 2012;26(11):1335-44
   Google Scholar
• Hodge W, Brown A, Kymes S, et al. Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 2010;45(3):223-30
   Google Scholar
• Miners A. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia 2013;19(2):174-80
   PubMed Web of Science ®Google Scholar
• Moolenaar LM, Vijgen SM, Hompes P, et al. Economic evaluation studies in reproductive medicine: a systematic review of methodologic quality. Fertil Steril 2013;99(6):1689-94
   Google Scholar
• Oxlade O, Pinto M, Trajman A, Menzies D. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. PLoS ONE 2013;8(3):e56044
   Google Scholar
• Ruger JP, Lazar CM. Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research. Annu Rev Public Health 2012;33:279-305
   Google Scholar
• Schwappach D, Popova S, Mohapatra S, et al. Strategies for evaluating the economic value of drugs in alcohol dependence treatment. Drug Alcohol Depend 2012;122(3):165-73
   Google Scholar
• Sun X, Qin WX, Li YP, Jiang XH. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: A systematic review of economic evidence. J Gastroenterol Hepatol 2007;22(9):1369-77
   Google Scholar
• Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn’s disease. Inflamm Bowel Dis 2013;19(12):2673-94
   PubMed Web of Science ®Google Scholar
• van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res 2011;63(1):65-78
   PubMed Web of Science ®Google Scholar
• Vijgen SM, Opmeer BC, Mol BW. The methodological quality of economic evaluation studies in obstetrics and gynecology: a systematic review. Am J Perinatol 2013;30(4):253-60
   Google Scholar
• Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder a systematic literature review. CNS Drugs 2012;26(7):581-600
   Google Scholar
• Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Curr Med Res Opin 2010;26(9):2105-18
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russel L, Weinstein M. Cost-Effectiveness in Health and Medicine. 1996
   Google Scholar
• Haji Ali Afzali H, Karnon J, Merlin T. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making 2013;33(3):325-32
   Google Scholar
• Frederix GW, Haji Ali Afzali H, Dasbach EJ, Ward RL. Development and use of disease-specific (reference) models for economic evaluations of health technologies: an overview of key issues and potential solutions. Pharmacoeconomics 2015. [Epub ahead of print]
   Google Scholar